CNSide® Secures Major Payor Coverage | Plus Therapeutics (NASDAQ: PSTV) at NYSE with StockTwits скачать в хорошем качестве

CNSide® Secures Major Payor Coverage | Plus Therapeutics (NASDAQ: PSTV) at NYSE with StockTwits

Plus Therapeutics (NASDAQ: PSTV) President & CEO, Marc Hedrick, MD, joined StockTwits’ Katie Perry at the New York Stock Exchange to discuss a major milestone: national coverage for the CNSide® CSF assay platform through both Humana and UnitedHealthcare. Dr. Hedrick highlights how CNSide® empowers clinicians with real-time, actionable insights for patients with leptomeningeal metastases and other central nervous system cancers. He also provides an update on REYOBIQ™ (rhenium [186Re] obisbemeda), the company’s targeted radiotherapeutic currently being evaluated in the ReSPECT clinical trials, and explains how these complementary platforms advance personalized cancer care. The discussion includes: • Newly secured national payor coverage from Humana and UnitedHealthcare • Plans to expand reimbursement access even further • How CNSide® delivers sensitive, quantitative tumor cell detection in cerebrospinal fluid • Progress across the REYOBIQ™ clinical development program • Plus Therapeutics’ broader mission to improve outcomes in CNS oncology About Plus Therapeutics and CNSide Diagnostics Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases. Learn More: PlusTherapeutics.com CNSide-Dx.com @CNSideDiagnostics